APEA 3P Exam Complete Study Guide; Multiple Choice
Questions & Answers (NP Board Review) - St Thomas University
- 200 Questions and Answers Already Graded A+ Premium
Exam Tested And Verified
Subject Area APEA 3P Exam - Advanced Health Assessment, Pathophysiology, and
Pharmacology
Description This comprehensive exam assesses the integration of advanced health assessment,
pathophysiology, and pharmacology knowledge required for nurse practitioner
board certification. It emphasizes clinical reasoning, evidence-based practice, and
application of current guidelines across diverse patient populations.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Synthesize pathophysiological mechanisms to formulate differential diagnoses
2. Apply pharmacokinetic and pharmacodynamic principles to prescribe safely
across the lifespan
3. Interpret advanced assessment findings to guide diagnostic and therapeutic
decisions
4. Evaluate the impact of comorbid conditions and polypharmacy on treatment
plans
Accreditation Designed to meet the rigor of top-tier US NP programs and board certification
standards (AANP, ANCC).
Page 1
,1. A patient with chronic kidney disease (stage 4) presents with hypertension and
edema. Current medications include lisinopril 40 mg daily and furosemide 40 mg
twice daily. Blood pressure is 158/92 mm Hg, heart rate 78 bpm, and serum
potassium 5.6 mEq/L. Which of the following adjustments to the antihypertensive
regimen is most appropriate?
A. Add spironolactone 25 mg daily
B. Increase lisinopril to 60 mg daily
C. Discontinue lisinopril and start amlodipine 5 mg daily
D. Add metoprolol tartrate 25 mg twice daily
Answer: C. Discontinue lisinopril and start amlodipine 5 mg daily
In stage 4 CKD with hyperkalemia (K+ 5.6), ACE inhibitors (lisinopril) should be
discontinued due to risk of worsening hyperkalemia. Spironolactone (A) also increases
potassium. Increasing lisinopril (B) would exacerbate hyperkalemia. Amlodipine (C) is
a calcium channel blocker that does not affect potassium and is safe in CKD.
Metoprolol (D) is not first-line for hypertension in CKD without specific indications like
coronary artery disease.
2. A 35-year-old female presents with fatigue, weight gain, cold intolerance, and
constipation. Laboratory results show TSH 12.5 mIU/L (normal 0.5-4.5), free T4 0.7
ng/dL (normal 0.8-1.8), and positive thyroid peroxidase antibodies. Which of the
following best explains the pathophysiology underlying this condition?
A. Autoimmune stimulation of TSH receptors leading to thyroid hormone excess
B. Destruction of thyroid follicular cells by cytotoxic T lymphocytes
C. Inhibition of thyroid peroxidase enzyme by autoantibodies
D. Resistance of peripheral tissues to thyroid hormone action
Answer: C. Inhibition of thyroid peroxidase enzyme by autoantibodies
This patient has Hashimoto thyroiditis, an autoimmune disorder where autoantibodies
inhibit thyroid peroxidase, reducing thyroid hormone synthesis. (A) describes Graves
disease (TSI). (B) is more characteristic of postpartum thyroiditis or subacute
thyroiditis. (D) is seen in thyroid hormone resistance syndromes, which typically
present with elevated T4 and TSH.
Page 2
,3. A 28-year-old male with no significant medical history presents with acute onset of
severe, colicky right flank pain radiating to the groin, associated with nausea and
hematuria. CT scan reveals a 7 mm ureteral stone at the ureterovesical junction.
Which of the following is the most appropriate initial management?
A. Extracorporeal shock wave lithotripsy (ESWL)
B. Ureteroscopy with laser lithotripsy
C. Medical expulsive therapy with tamsulosin and hydration
D. Percutaneous nephrolithotomy
Answer: C. Medical expulsive therapy with tamsulosin and hydration
For a 7 mm distal ureteral stone, medical expulsive therapy (MET) with tamsulosin
(alpha-blocker) and increased fluid intake is first-line, as stones 10 mm often pass
spontaneously. (A) ESWL is indicated for renal stones or proximal ureteral stones, not
typically for distal stones. (B) Ureteroscopy is reserved for failed MET or larger stones.
(D) Percutaneous nephrolithotomy is for large (>2 cm) renal stones.
4. A 72-year-old male with type 2 diabetes, hypertension, and coronary artery
disease is started on metformin and atorvastatin. He develops diffuse myalgias and
dark urine. Laboratory findings: creatine kinase 12,000 U/L, serum creatinine 1.8
mg/dL (baseline 1.0), and urinalysis positive for blood without red cells. What is the
most likely cause of his symptoms?
A. Statin-induced rhabdomyolysis exacerbated by metformin
B. Acute interstitial nephritis due to atorvastatin
C. Metformin-associated lactic acidosis
D. Diabetic nephropathy progression
Answer: A. Statin-induced rhabdomyolysis exacerbated by metformin
The combination of myalgias, markedly elevated CK, dark urine (myoglobinuria), and
acute kidney injury is classic for rhabdomyolysis. Statins like atorvastatin can cause
rhabdomyolysis, especially with risk factors like advanced age, diabetes, and
polypharmacy. Metformin does not directly cause rhabdomyolysis but may increase
risk if renal function declines. (B) Interstitial nephritis typically presents with sterile
pyuria and eosinophils. (C) Lactic acidosis presents with anion gap acidosis, not
myalgias. (D) Diabetic nephropathy progresses slowly, not acutely.
Page 3
, 5. A 45-year-old female with a history of migraines presents with a severe, unilateral
throbbing headache associated with photophobia and nausea, lasting 6 hours. She
has tried ibuprofen 800 mg without relief. She has no contraindications to triptans.
Which of the following is the most appropriate acute treatment?
A. Sumatriptan 6 mg subcutaneous injection
B. Rizatriptan 10 mg orally disintegrating tablet
C. Dihydroergotamine 1 mg intramuscular
D. Opioid analgesic such as hydromorphone
Answer: A. Sumatriptan 6 mg subcutaneous injection
For severe migraine with nausea and photophobia that is not relieved by NSAIDs, a
parenteral triptan is recommended. Subcutaneous sumatriptan has the fastest onset
(10-15 minutes) and highest efficacy. (B) Oral rizatriptan is effective but absorption
may be delayed with nausea. (C) Dihydroergotamine is a second-line agent due to more
side effects. (D) Opioids are not recommended due to risk of medication overuse
headache and limited efficacy.
6. A 55-year-old male with a 30-pack-year smoking history presents with dyspnea on
exertion, chronic cough, and wheezing. Spirometry shows FEV1/FVC 0.62, FEV1
55% predicted, with no significant bronchodilator response. He has had two
exacerbations in the past year requiring antibiotics and corticosteroids. According to
GOLD guidelines, which of the following is the most appropriate initial
pharmacotherapy?
A. Inhaled corticosteroid (ICS) alone
B. Long-acting beta-agonist (LABA) alone
C. Long-acting muscarinic antagonist (LAMA) alone
D. LAMA + LABA combination
Answer: C. Long-acting muscarinic antagonist (LAMA) alone
This patient has GOLD stage 2 COPD (FEV1 50-79%) with exacerbations (group E).
GOLD 2023 recommends initial therapy with LAMA for group E patients. LAMA
reduces exacerbations more than LABA. (A) ICS alone is not recommended; ICS is
used in combination with LABA for patients with eosinophilia or frequent
exacerbations despite LAMA/LABA. (B) LABA alone is less effective for exacerbation
prevention. (D) LAMA+LABA is an alternative for group E, but LAMA alone is
first-line per GOLD.
Page 4
Questions & Answers (NP Board Review) - St Thomas University
- 200 Questions and Answers Already Graded A+ Premium
Exam Tested And Verified
Subject Area APEA 3P Exam - Advanced Health Assessment, Pathophysiology, and
Pharmacology
Description This comprehensive exam assesses the integration of advanced health assessment,
pathophysiology, and pharmacology knowledge required for nurse practitioner
board certification. It emphasizes clinical reasoning, evidence-based practice, and
application of current guidelines across diverse patient populations.
Expected Grade A+
Total Questions 200
Duration 3 hours
Learning Outcomes 1. Synthesize pathophysiological mechanisms to formulate differential diagnoses
2. Apply pharmacokinetic and pharmacodynamic principles to prescribe safely
across the lifespan
3. Interpret advanced assessment findings to guide diagnostic and therapeutic
decisions
4. Evaluate the impact of comorbid conditions and polypharmacy on treatment
plans
Accreditation Designed to meet the rigor of top-tier US NP programs and board certification
standards (AANP, ANCC).
Page 1
,1. A patient with chronic kidney disease (stage 4) presents with hypertension and
edema. Current medications include lisinopril 40 mg daily and furosemide 40 mg
twice daily. Blood pressure is 158/92 mm Hg, heart rate 78 bpm, and serum
potassium 5.6 mEq/L. Which of the following adjustments to the antihypertensive
regimen is most appropriate?
A. Add spironolactone 25 mg daily
B. Increase lisinopril to 60 mg daily
C. Discontinue lisinopril and start amlodipine 5 mg daily
D. Add metoprolol tartrate 25 mg twice daily
Answer: C. Discontinue lisinopril and start amlodipine 5 mg daily
In stage 4 CKD with hyperkalemia (K+ 5.6), ACE inhibitors (lisinopril) should be
discontinued due to risk of worsening hyperkalemia. Spironolactone (A) also increases
potassium. Increasing lisinopril (B) would exacerbate hyperkalemia. Amlodipine (C) is
a calcium channel blocker that does not affect potassium and is safe in CKD.
Metoprolol (D) is not first-line for hypertension in CKD without specific indications like
coronary artery disease.
2. A 35-year-old female presents with fatigue, weight gain, cold intolerance, and
constipation. Laboratory results show TSH 12.5 mIU/L (normal 0.5-4.5), free T4 0.7
ng/dL (normal 0.8-1.8), and positive thyroid peroxidase antibodies. Which of the
following best explains the pathophysiology underlying this condition?
A. Autoimmune stimulation of TSH receptors leading to thyroid hormone excess
B. Destruction of thyroid follicular cells by cytotoxic T lymphocytes
C. Inhibition of thyroid peroxidase enzyme by autoantibodies
D. Resistance of peripheral tissues to thyroid hormone action
Answer: C. Inhibition of thyroid peroxidase enzyme by autoantibodies
This patient has Hashimoto thyroiditis, an autoimmune disorder where autoantibodies
inhibit thyroid peroxidase, reducing thyroid hormone synthesis. (A) describes Graves
disease (TSI). (B) is more characteristic of postpartum thyroiditis or subacute
thyroiditis. (D) is seen in thyroid hormone resistance syndromes, which typically
present with elevated T4 and TSH.
Page 2
,3. A 28-year-old male with no significant medical history presents with acute onset of
severe, colicky right flank pain radiating to the groin, associated with nausea and
hematuria. CT scan reveals a 7 mm ureteral stone at the ureterovesical junction.
Which of the following is the most appropriate initial management?
A. Extracorporeal shock wave lithotripsy (ESWL)
B. Ureteroscopy with laser lithotripsy
C. Medical expulsive therapy with tamsulosin and hydration
D. Percutaneous nephrolithotomy
Answer: C. Medical expulsive therapy with tamsulosin and hydration
For a 7 mm distal ureteral stone, medical expulsive therapy (MET) with tamsulosin
(alpha-blocker) and increased fluid intake is first-line, as stones 10 mm often pass
spontaneously. (A) ESWL is indicated for renal stones or proximal ureteral stones, not
typically for distal stones. (B) Ureteroscopy is reserved for failed MET or larger stones.
(D) Percutaneous nephrolithotomy is for large (>2 cm) renal stones.
4. A 72-year-old male with type 2 diabetes, hypertension, and coronary artery
disease is started on metformin and atorvastatin. He develops diffuse myalgias and
dark urine. Laboratory findings: creatine kinase 12,000 U/L, serum creatinine 1.8
mg/dL (baseline 1.0), and urinalysis positive for blood without red cells. What is the
most likely cause of his symptoms?
A. Statin-induced rhabdomyolysis exacerbated by metformin
B. Acute interstitial nephritis due to atorvastatin
C. Metformin-associated lactic acidosis
D. Diabetic nephropathy progression
Answer: A. Statin-induced rhabdomyolysis exacerbated by metformin
The combination of myalgias, markedly elevated CK, dark urine (myoglobinuria), and
acute kidney injury is classic for rhabdomyolysis. Statins like atorvastatin can cause
rhabdomyolysis, especially with risk factors like advanced age, diabetes, and
polypharmacy. Metformin does not directly cause rhabdomyolysis but may increase
risk if renal function declines. (B) Interstitial nephritis typically presents with sterile
pyuria and eosinophils. (C) Lactic acidosis presents with anion gap acidosis, not
myalgias. (D) Diabetic nephropathy progresses slowly, not acutely.
Page 3
, 5. A 45-year-old female with a history of migraines presents with a severe, unilateral
throbbing headache associated with photophobia and nausea, lasting 6 hours. She
has tried ibuprofen 800 mg without relief. She has no contraindications to triptans.
Which of the following is the most appropriate acute treatment?
A. Sumatriptan 6 mg subcutaneous injection
B. Rizatriptan 10 mg orally disintegrating tablet
C. Dihydroergotamine 1 mg intramuscular
D. Opioid analgesic such as hydromorphone
Answer: A. Sumatriptan 6 mg subcutaneous injection
For severe migraine with nausea and photophobia that is not relieved by NSAIDs, a
parenteral triptan is recommended. Subcutaneous sumatriptan has the fastest onset
(10-15 minutes) and highest efficacy. (B) Oral rizatriptan is effective but absorption
may be delayed with nausea. (C) Dihydroergotamine is a second-line agent due to more
side effects. (D) Opioids are not recommended due to risk of medication overuse
headache and limited efficacy.
6. A 55-year-old male with a 30-pack-year smoking history presents with dyspnea on
exertion, chronic cough, and wheezing. Spirometry shows FEV1/FVC 0.62, FEV1
55% predicted, with no significant bronchodilator response. He has had two
exacerbations in the past year requiring antibiotics and corticosteroids. According to
GOLD guidelines, which of the following is the most appropriate initial
pharmacotherapy?
A. Inhaled corticosteroid (ICS) alone
B. Long-acting beta-agonist (LABA) alone
C. Long-acting muscarinic antagonist (LAMA) alone
D. LAMA + LABA combination
Answer: C. Long-acting muscarinic antagonist (LAMA) alone
This patient has GOLD stage 2 COPD (FEV1 50-79%) with exacerbations (group E).
GOLD 2023 recommends initial therapy with LAMA for group E patients. LAMA
reduces exacerbations more than LABA. (A) ICS alone is not recommended; ICS is
used in combination with LABA for patients with eosinophilia or frequent
exacerbations despite LAMA/LABA. (B) LABA alone is less effective for exacerbation
prevention. (D) LAMA+LABA is an alternative for group E, but LAMA alone is
first-line per GOLD.
Page 4
